Revvity at 2026 Global Healthcare Conference: growth, AI and backlog

Revvity reported Q2 2025 results above internal expectations, led by 11% organic diagnostics growth, and raised full-year diagnostics guidance to high single digits. Life sciences organic growth fell 3% as software declined 20% on contract timing and difficult comparisons, but instruments and consumables grew low single digits and instrument backlog reached its strongest level in 3-5 years, with book-to-bill above 1.0. Management expects software growth to rebound to the high teens in Q3 and mid-to-high teens in Q4, while AI-driven drug discovery demand supports high-content screening; the company also highlighted over 100% year-to-date free-cash-flow conversion, a July bond payoff, and 15% share repurchases across 2024-25.

Analysis

RVTY’s investable setup is a quality-versus-valuation question, not a clean AI proxy. The earnings bridge into the next report relies heavily on backlog conversion, license-recognition timing and easier comparisons; each can improve reported growth without establishing a durable acceleration in underlying laboratory spending. At a premium multiple, the stock needs evidence that instrument orders are broadening beyond one high-content screening category and that consumables follow placements at attractive pull-through rates.

The most material upside catalyst over 1-3 months is a clean confirmation of the anticipated second-half software recovery alongside life-science margin expansion. A software rebound would remove the easiest bear argument, while stronger incremental margins could drive estimate revisions disproportionate to revenue growth. The 6-18 month upside case rests on usage-based software monetization and AI-driven preclinical workflows, but those are option value rather than near-term earnings support; customers may use AI to reduce experimental failure rates and laboratory spend per program, rather than simply increase test volumes.

Downside asymmetry is elevated in a rising-yield tape: RVTY screens as a long-duration healthcare growth asset while organic growth remains uneven. A failure to convert backlog on schedule, another deferral of large orders, or a guidance reset tied to academic budgets would likely compress both earnings estimates and the valuation premium. The unquantified backlog and management’s refusal to update intra-quarter conditions make the conference commentary insufficient to underwrite an incremental long at current levels.

Contrarian point: the best near-term beneficiary of AI drug discovery may be customers such as LLY, which can internalize productivity gains, rather than tool vendors competing to capture a limited equipment budget. RVTY’s differentiation must show up in sustained order growth, recurring consumables and software consumption—not merely in customer experimentation with AI connectors.

Key Decisions for Investors

• Do not initiate an outright RVTY long ahead of the next earnings report; establish a watch trigger only if life-science organic growth turns positive with instrument growth at or above mid-single digits and software growth rebounds as indicated. A miss on either metric should be treated as evidence that the premium multiple lacks support.
• For existing RVTY exposure, reduce position size or hedge through the report with a 1-3 month put spread, targeting protection against a 15-20% drawdown. The hedge is justified by valuation sensitivity to higher real yields and the dependence on timing-related revenue recovery.
• Conditional pair trade after confirmed execution: long RVTY / short PFE over 6-12 months. RVTY offers exposure to preclinical research intensity and diagnostics mix, while PFE remains more dependent on pipeline replacement and mature-product cash flows; exit if RVTY fails to sustain positive life-science growth or if PFE delivers a material pipeline catalyst.
• Monitor LLY’s R&D spend and AI-discovery disclosures as a read-through for end-market demand, but do not infer RVTY revenue from AI announcements alone. Escalate the RVTY thesis only if large-pharma capex/R&D budgets translate into broad-based tool orders rather than isolated screening-system purchases.